First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

Autor: Narayan, Rupa, Piérola, Ana Alfonso, Donnellan, William B., Yordi, Antonieta Molero, Abdul‐Hay, Maher, Platzbecker, Uwe, Subklewe, Marion, Kadia, Tapan Mahendra, Alonso‐Domínguez, Juan Manuel, McCloskey, James, Bradford, Kathryn, Curtis, Martin, Daskalakis, Nikki, Guttke, Christina, Safer, Karim, Hiebert, Brett, Murphy, Joseph, Li, Xiang, Duchin, Ken, Esteban, Daniel

Publikováno v: CTS: Clinical & Translational Science; Mar2024, Vol. 17 Issue 3, p1-18, 18p

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.

Autor: Karkera, Jayaprakash, Steiner, Hannes, Li, Weimin, Skradski, Viktor, Moser, Patrizia L., Riethdorf, Sabine, Reddy, Manjula, Puchalski, Thomas, Safer, Karim, Prabhakar, Uma, Pantel, Klaus, Qi, Ming, Culig, Zoran

Publikováno v: Prostate; Sep2011, Vol. 71 Issue 13, p1455-1465, 11p

Drug-inducible, dendritic cell-based genetic immunization.

Autor: Timares L; Center for Biomedical Inventions, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. timares@uab.edu, Safer KM, Qu B, Takashima A, Johnston SA

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2003 Jun 01; Vol. 170 (11), pp. 5483-90.